CytoMed Therapeutics Limited
GDTC · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $106 | $100 | $52 | $109 |
| % Growth | 5.7% | 90.9% | -51.7% | – |
| Cost of Goods Sold | $7 | $7 | $11 | $11 |
| Gross Profit | $98 | $93 | $92 | $97 |
| % Margin | 93.1% | 93.1% | 174.9% | 89.7% |
| R&D Expenses | $457 | $433 | $342 | $364 |
| G&A Expenses | $0 | $0 | $118 | $126 |
| SG&A Expenses | $152 | $144 | $124 | $131 |
| Sales & Mktg Exp. | $0 | $0 | $6 | $6 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $609 | $576 | $466 | $495 |
| Operating Income | -$511 | -$483 | -$1,231 | -$398 |
| % Margin | -483% | -483% | -2,348.6% | -366.3% |
| Other Income/Exp. Net | -$373 | -$353 | $150 | -$160 |
| Pre-Tax Income | -$883 | -$836 | -$1,079 | -$558 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$882 | -$835 | -$1,077 | -$556 |
| % Margin | -834.7% | -834.7% | -2,055.1% | -511.6% |
| EPS | -0.075 | -0.071 | -0.093 | -0.048 |
| % Growth | -5.7% | 24.2% | -93.6% | – |
| EPS Diluted | -0.075 | -0.071 | -0.093 | -0.048 |
| Weighted Avg Shares Out | 11,809 | 11,809 | 11,540 | 11,540 |
| Weighted Avg Shares Out Dil | 11,809 | 11,809 | 11,540 | 11,540 |
| Supplemental Information | – | – | – | – |
| Interest Income | $65 | $0 | $96 | $45 |
| Interest Expense | $8 | $4 | $8 | $0 |
| Depreciation & Amortization | $71 | $67 | $60 | $63 |
| EBITDA | -$804 | -$761 | -$482 | -$513 |
| % Margin | -760.9% | -760.9% | -920.4% | -472% |